BEIJING – Chinese authorities have indicted British and American investigators hired by GlaxoSmithKline on charges of illegally obtaining and selling private information, state media reported Monday, as the Briton blamed the pharmaceutical company for misleading and using him.
Prosecutors in Shanghai filed charges of illegally obtaining and selling private information against British investigator Peter Humphrey and his wife, Yingzeng Yu, a U.S. citizen, at the city’s No. 1 Intermediate People’s Court, the official Xinhua News Agency said. The move paves the way for the couple to stand trial.
Xinhua said it is the first time foreigners have faced such charges in China. Humphrey, 58, and Yu, 61, are part of an industry of investigators who help corporate clients screen potential partners and employees or watch for embezzlement and other employee misconduct.
The couple’s arrest last year coincided with a Chinese investigation of accusations that GlaxoSmithKline paid bribes to doctors and officials to use its medications. Glaxo said it hired Yu and Humphrey last year to investigate a security breach involving a top manager.
The indictment received prominent coverage in China. Reports by state broadcaster CCTV showed Humphrey and his wife being separately interviewed by Chinese reporters. In CCTV’s footage, they were shown seated and wearing orange vests that are typical uniforms of detainees, as they spoke to reporters.
According to Xinhua, the couple are accused of illegally selling a “huge amount” of personal information on Chinese citizens, including home addresses, information about family members, details about real estate and vehicles and records of travelers entering and leaving the country.
The investigators are accused of obtaining such information by illegally buying it from others as well as with hidden cameras or by following people, Xinhua said.
Yu and Humphrey compiled the information gathered on the subjects of their investigations and sold the reports to clients that were mainly multinational companies based in China such as GSK China, the report said.
In Chinese media reports on Monday, Humphrey said he was contacted in April last year by Mark Reilly, who was GSK’s China manager at the time, who wanted him to find out who leaked allegations of bribery at the firm to Chinese authorities and senior executives at the firm.
Reilly, who is British, is at the center of a major investigation into corruption in China’s medical industry. In May, he was accused of leading a sprawling scheme to bribe doctors and hospitals to use GSK’s drugs. Reilly’s case has been turned over to prosecutors.
Humphrey said on state television that he found out during his investigation that the bribery claims were true and if he had known that earlier he would not have carried out the probe. Humphrey said he felt “betrayed and used” by the pharmaceutical firm.
Executives at GSK did not immediately respond to emailed requests for comment.